Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Valiente · SciRah

Researcher profile · Semantic Scholar

C. Valiente

Share profile

C. Valiente — researcher profile on SciRah

h-index: 2
Works: 15
Citations: 81

Most-cited papers

Outcome of liver transplantation using donors older than 60 year of age
M. T. Serrano, A. Garcia-gil, J. Arenas, Y. Ber +3 more
2010Clinical Transplantation63 citations
Semantic Scholar
Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA).
C. Valiente, M. Borrell, A. Fernández, A. Templeton +6 more
2018Annals of Oncology15 citations Open access
Semantic Scholar
1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
A. Rodríguez, C. Valiente, J. Tapia, I. Gich +3 more
20201 citations Open access
Semantic Scholar
Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
A. Rodríguez, J. Tapia, T. Hwang, C. Valiente +4 more
2019Annals of Oncology1 citations Open access
Semantic Scholar
1435O_PRComparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
C. Valiente, A. Tibau, A. Fernández, A. Templeton +5 more
20171 citations Open access
Semantic Scholar
P1.07-028 Determination of Soluble PD-L1 as a Potential Biomarker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)
A. Joaquín, C. Z. Atenza, S. V. Alcorisa, I. Sullivan +14 more
20171 citations Open access
Semantic Scholar
1638P Are all leiomyosarcomas created equal? Clinical characteristics and experience of a single reference centre
R. T. Lleida, B. M. Cullell, M. Puy, A. Rodríguez +13 more
20200 citations Open access
Semantic Scholar
1583O Clinical benefit of cancer drugs approved in Switzerland during the last decade
R. Adam, A. Tibau, C. Valiente, B. Šeruga +3 more
2020Annals of Oncology0 citations Open access
Semantic Scholar
Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs.
C. Valiente, M. Borrell, T. Hwang, I. Gich Saladich +4 more
2018Annals of Oncology0 citations Open access
Semantic Scholar
Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs).
M. Melià, I. Sullivan, A. Joaquín, G. A. Palacios +13 more
2018Annals of Oncology0 citations Open access
Semantic Scholar
P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
M. Melià, I. Sullivan, A. Joaquín, G. A. Palacios +16 more
2018Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
M. Melià, I. Sullivan, A. Joaquín, G. A. Palacios +16 more
20180 citations Open access
Semantic Scholar
Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval.
M. Puy, C. Valiente, K. Vokinger, T. Hwang +7 more
2018Annals of Oncology0 citations Open access
Semantic Scholar
1441PDMagnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours
C. Valiente, E. Amir, A. Fernández, A. Templeton +5 more
20170 citations Open access
Semantic Scholar
1437O_PRClinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval
M. Puy, C. Valiente, A. Fernández, A. Templeton +5 more
20170 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Tibau×9
Invite
A. Tibau — researcher profile on SciRah
A. Templeton×7
Invite
A. Templeton — researcher profile on SciRah
A. Barnadas×7
Invite
A. Barnadas — researcher profile on SciRah
E. Amir×7
Invite
E. Amir — researcher profile on SciRah

×5

Invite

A. Fernández — researcher profile on SciRah

L. Del Carpio Huerta×5

Invite

L. Del Carpio Huerta — researcher profile on SciRah

Invite

M. Melià — researcher profile on SciRah

Invite

A. Joaquín — researcher profile on SciRah

Invite

I. Sullivan — researcher profile on SciRah

G. A. Palacios×4

Invite

G. A. Palacios — researcher profile on SciRah

Invite

P. G. Pons — researcher profile on SciRah

S. D. Camacho Arellano×4